Sugi Predict

Sugi Predict / Targets / TEK

TEK

Angiopoietin-1 receptor · Q02763 · TEK on Sugi Atlas →

92,326 patent compounds predicted against TEK, 67,781 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL67977 SCHEMBL67977 0.60 11/20
SCHEMBL66952 SCHEMBL66952 0.59 11/20
SCHEMBL115284 SCHEMBL115284 0.81 9/20
SCHEMBL67988 SCHEMBL67988 0.62 7/20
SCHEMBL66928 SCHEMBL66928 0.60 7/20
SCHEMBL120665 SCHEMBL120665 0.46 7/20
SCHEMBL121795 SCHEMBL121795 0.45 7/20
SCHEMBL121796 SCHEMBL121796 0.45 7/20
SCHEMBL121511 SCHEMBL121511 0.44 7/20
SCHEMBL120357 SCHEMBL120357 0.51 6/20
SCHEMBL123604 SCHEMBL123604 0.47 6/20
SCHEMBL67231 SCHEMBL67231 0.46 6/20
SCHEMBL123025 SCHEMBL123025 0.46 6/20
SCHEMBL123026 SCHEMBL123026 0.46 6/20
SCHEMBL122860 SCHEMBL122860 0.45 6/20
SCHEMBL122968 SCHEMBL122968 0.45 6/20
SCHEMBL58313 SCHEMBL58313 0.59 5/20
SCHEMBL58543 SCHEMBL58543 0.57 5/20
SCHEMBL67146 SCHEMBL67146 0.51 5/20
SCHEMBL60366 SCHEMBL60366 0.47 5/20

Clinical trials — most relevant to TEK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs PHASE4COMPLETED
Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma PHASE3COMPLETED
A Prospective Randomized Trial of Pre-Operative IMRT+Surgery Versus Surgery Alone For Primary Retroperitoneal Sarcoma PHASE3COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia. PHASE2RECRUITING
Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases PHASE2COMPLETED
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
Clinical Use of Stem Cells for the Treatment of Covid-19 PHASE1/PHASE2COMPLETED
An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer PHASE2COMPLETED
AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme PHASE2COMPLETED
Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M PHASE2COMPLETED
Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma PHASE2ACTIVE_NOT_RECRUITING
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients PHASE2ENROLLING_BY_INVITATION
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma PHASE2COMPLETED
Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy PHASE2COMPLETED
Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) PHASE2COMPLETED
Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer PHASE2COMPLETED
Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity: A Randomized and Prospective Study PHASE1/PHASE2COMPLETED
Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC PHASE1/PHASE2UNKNOWN
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration PHASE1COMPLETED
Infection, Sepsis and Meningitis in Surinamese Neonates nanCOMPLETED
Efficacy and Safety of Cold Atmospheric Plasma Combined With Endovascular Intervention in Patients With Diabetic Foot Ulcers and Lower Extremity Arterial Occlusion nanRECRUITING
Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis nanCOMPLETED
EVLWI Exhibits Pulmonary and Systemic Permeability in Sepsis Related ALI/ARDS nanUNKNOWN
HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion nanACTIVE_NOT_RECRUITING
The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis nanUNKNOWN
Genetic Biomarkers for the Response to Anti-VEGF (Vascular Endothelial Growth Factor).Treatment in Wet Age-related Macular Degeneration (Wet ARMD) nanCOMPLETED
Effect of Hypoxic Exposure on Blood Variables in Elite Wrestlers nanCOMPLETED
Vascular Biomarkers Predictive of the Progression From Hypertensive Disorders in Pregnancy to Preeclampsia in Pregnant Women nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a TEK binder may also engage these)

ProteinNameSimilarity
Q02858 — 1.000 Q02858 →
Q06807 — 1.000 Q06807 →
Q8JFR5 — 0.997 Q8JFR5 →
EPHA6 Ephrin type-A receptor 6 0.996 landscape →
P26619 — 0.995 P26619 →
PTPRM Receptor-type tyrosine-protein phosphatase mu 0.995 landscape →
P54757 — 0.995 P54757 →
Q00495 — 0.995 Q00495 →
P43481 — 0.995 P43481 →
Q9I8N6 — 0.995 Q9I8N6 →
Q28889 — 0.995 Q28889 →
Q2HWD6 — 0.995 Q2HWD6 →
Q76II0 — 0.994 Q76II0 →
Q28317 — 0.994 Q28317 →
Q62413 — 0.994 Q62413 →
Q8AXC7 — 0.994 Q8AXC7 →
EPHA5 Ephrin type-A receptor 5 0.994 landscape →
P79750 — 0.993 P79750 →
P05532 — 0.993 P05532 →
Q91735 — 0.993 Q91735 →
O08680 — 0.993 O08680 →
Q91909 — 0.993 Q91909 →
Q07498 — 0.993 Q07498 →
P54755 — 0.993 P54755 →
P35546 — 0.993 P35546 →
P52583 — 0.993 P52583 →
Q08156 — 0.993 Q08156 →
Q60629 — 0.993 Q60629 →
Q90344 — 0.993 Q90344 →
Q5GIT4 — 0.992 Q5GIT4 →